Tuna Salad Products Recall Map Shows States With New Warning
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Albertsons, Randalls and Tom Thumb stores in four states are recalling certain items containing tuna salad supplied by Reser's Fine Foods due to fears of potential Listeria contamination.
Newsweek reached out to Albertsons via email Monday night for comment.
Why It Matters
Listeria monocytogenes is a bacterium capable of causing serious and sometimes fatal infections, especially in pregnant women, older adults, infants, and people with weakened immune systems. Pregnant women are about 10 times more likely to be infected, and those from Hispanic backgrounds face an even higher risk. For these individuals, exposure can result in miscarriage, stillbirth, hospitalization, or death. The FDA describes listeriosis as the third leading cause of death from food poisoning in the United States.
Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens.
Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts.
What To Know
The FDA says in their alert, that there have been no reports of injuries or illnesses related to the recall.
"Anyone concerned about an injury or illness should contact a healthcare provider," the FDA says.
The alert also lists in a chart the product details for the impacted tuna salad items with corresponding UPC numbers, sizes and sell through dates.
Below is a map of the states impacted by the recall, which includes Arkansas, Texas, Louisiana, and Oklahoma.
What People Are Saying
The FDA in part in the alert: "The FDA recommends in these cases that anyone who purchased or received any recalled products to use extra vigilance in cleaning and sanitizing any surfaces and containers that may have come in contact with these products to reduce the risk of cross-contamination. Listeria monocytogenes can survive in refrigerated temperatures and can easily spread to other foods and surfaces."
What Happens Next
People who have purchased the recalled product are urged to throw the product away or return it to the original place of purchase for a full refund, the FDA says.
Those with additional questions may contact Albertsons Companies' Customer Service Center on weekday at 1-877-723-3929 from 5 a.m. to 9 p.m. PT.
Consumers can also find updates and comprehensive advice on minimizing listeria risks at the FDA's food safety page. Those at high risk should consider additional preventative measures, including using refrigerator thermometers, consuming ready-to-eat foods promptly, and avoiding high-risk foods such as unpasteurized cheeses and smoked seafood unless heated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR
Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032. San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032. This extraordinary growth is propelled by the increasing adoption of bispecific antibody therapies in oncology and immunology, groundbreaking clinical outcomes, and robust R&D investments aimed at next-generation biologics. Bispecific antibodies are bioengineered molecules designed to simultaneously recognize and bind to two different antigens or epitopes. Unlike monoclonal antibodies that target a single antigen, bispecific antibodies can link a disease-related antigen (such as one found on cancer cells) to another molecule—often a T-cell—thus redirecting immune cells to attack malignant tissues with heightened precision. This dual-binding capability is unlocking new therapeutic possibilities in cancer, autoimmune diseases, and infectious diseases. As of 2024, over 300 bispecific antibodies are in global clinical development, with 14 already approved by the U.S. FDA, reflecting the sector's rapid growth and clinical validation. Download Free Sample Report PDF @ Global Bispecific Antibodies Market Key Players- Detailed Competitive Insights Amgen Genentech Akeso, Inc. Taisho Pharmaceutical Janssen Immunocore Adimab, Innovent Biologics, Inc. AstraZeneca Affimed GmbH Xencor F. Hoffmann-La Roche Ltd. Sanofi Regeneron Pharmaceuticals Inc. Pieris Pharmaceuticals, Inc. Eli Lilly Mereo BioPharma Group plc Merus MacroGenics, Inc. Sobi, TG Therapeutics Inc. Genmab A/S Alteogen Emergent BioSolutions Inc. Novartis AG Astellas Pharma Inc. Celgene Corporation Others Market Drivers 1. Increasing Cancer Prevalence Globally Cancer remains a global health crisis, with the World Health Organization (WHO) estimating around 19.3 million new cancer cases and nearly 10 million deaths in 2023 alone. Traditional therapies are often limited by poor specificity and severe side effects, which have shifted the focus toward more targeted modalities, such as bispecific antibodies. Their unique mechanism allows precise tumor targeting while preserving healthy tissues, making them a preferred choice for next-gen cancer therapies. 2. Regulatory Approvals and Accelerated Development Pathways The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have actively supported innovative antibody therapeutics. Between 2022 and 2024, the FDA approved six bispecific antibodies, a testament to their growing clinical value. Regulatory agencies are also introducing expedited pathways for breakthrough therapies, speeding up market entry for promising candidates. 3. Rising Investments in Immunotherapy and Biologics Governments and private players are significantly boosting funding for immunotherapy research. For instance, the U.S. National Cancer Institute (NCI) allocated over USD 15 billion toward cancer research in 2023, a portion of which is directed toward the development of targeted therapies, including bispecific antibodies. This capital influx is catalyzing clinical trials, molecule discovery, and scalable manufacturing solutions. Market Challenges Despite the optimistic trajectory, the bispecific antibodies market faces notable challenges: Complex Manufacturing: Producing bispecific antibodies involves intricate processes, such as protein folding and stability optimization, which increase production time and cost. High Development Costs: The R&D cycle for bispecific therapies is long and resource-intensive, often requiring large-scale trials and advanced biotechnological platforms. Immunogenicity Risks: Some bispecific formats can trigger unwanted immune responses, complicating their clinical profiles. Nonetheless, advances in antibody engineering, such as the development of Fc-engineered antibodies and T-cell engaging bispecifics (BiTEs), are helping overcome these limitations. Regional Insights North America is poised to maintain a dominant position in the global bispecific antibodies market. Its leadership is driven by: A well-established biotech and pharma industry. Substantial government and private R&D investments. Early and streamlined regulatory approvals. In 2023 alone, the U.S. government dedicated nearly USD 7.9 billion toward cancer research, a portion of which supports novel antibody-based treatments. Moreover, the presence of major biopharmaceutical companies and academic research centers ensures rapid clinical development. Asia-Pacific, on the other hand, is anticipated to experience the fastest growth rate. Countries such as China, India, and South Korea are: Increasing healthcare expenditures. Encouraging local biotech innovation. Expanding access to clinical trials and biologic therapies. China, for example, is investing heavily in biologics manufacturing capabilities and has introduced supportive regulations for fast-track drug approval, which will likely make the region a future hub for bispecific antibody development. TABLE OF CONTENT 1. Bispecific Antibodies Market Overview 1.1. Study Scope 1.2. Market Estimation Years 2. Executive Summary 2.1. Market Snippet 2.1.1. Bispecific Antibodies Market Snippet by Drug Type 2.1.2. Bispecific Antibodies Market Snippet by Indication 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel 2.1.4. Bispecific Antibodies Market Snippet by Country 2.1.5. Bispecific Antibodies Market Snippet by Region 2.2. Competitive Insights 3. Bispecific Antibodies Key Market Trends 3.1. Bispecific Antibodies Market Drivers 3.1.1. Impact Analysis of Market Drivers 3.2. Bispecific Antibodies Market Restraints 3.2.1. Impact Analysis of Market Restraints 3.3. Bispecific Antibodies Market Opportunities 3.4. Bispecific Antibodies Market Future Trends…… Get a detailed analysis on regions, market segments, customer landscape, and companies@ Market Segmentation by Indication The bispecific antibodies market is segmented by application into: Cancer Autoimmune and Inflammatory Disorders Others Among these, the oncology segment is forecasted to command the largest share throughout the forecast period. As of March 2025, over 650 bispecific antibodies are in clinical development globally—nearly all focused on oncology applications, and nine of the 11 bispecifics approved since 2021 target cancer, representing over 80% of recent regulatory approvals. Competitive Landscape & Innovation Strategies The bispecific antibody space is rapidly evolving with heightened competition among biotech giants and emerging players. Leading companies are prioritizing: Next-generation platforms for greater safety, flexibility, and efficacy. Strategic collaborations and licensing deals to expand pipeline access. Geographic expansion into emerging economies with rising healthcare demands. Biotech firms are utilizing AI-driven drug discovery, cell-line optimization, and novel bispecific formats (like dual-variable domain antibodies and knob-into-hole technologies) to advance their products. Some players are also entering into co-development agreements to reduce costs and accelerate regulatory milestones. Future Outlook The bispecific antibodies market is positioned at the forefront of immunotherapeutic innovation. With strong clinical potential, increasing funding, and a favorable regulatory climate, the sector is expected to witness substantial growth through 2032. As manufacturing bottlenecks are resolved and newer formats with improved safety emerge, bispecific antibodies will likely become standard components of combination therapies in oncology and immune-related disorders. In conclusion, the bispecific antibodies market offers immense opportunities for stakeholders across biotechnology, healthcare, and investment sectors. Its rapid evolution signals a paradigm shift in how complex diseases are treated, ushering in a new era of precision medicine. Browse more Reports from AnalystView Market Insights:CONTACT: U.S. Office: 11923 NE Sumner St STE 750924 Portland, Oregon, 97220, USA Phone: +1 615-326-5253 (U.S. Toll Free) Email: mayank@ Email: inquiry@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
an hour ago
- UPI
DOJ drops challenge to Tennessee's gender care ban for minors
Participants walk up Market Street in the 55th annual San Francisco Pride Parade in San Francisco on Sunday, June 29, 2025. On Monday, the Justice Department dropped a lawsuit challenging Tennessee's ban on minors receiving gender-affirming medical care. File Photo by Terry Schmitt/UPI | License Photo July 22 (UPI) -- The Justice Department has dismissed a Biden-era lawsuit challenging Tennessee's law banning gender-affirming care for minors, as the Trump administration continues to attack the rights and medical care of transgender Americans. Attorney General Pam Bondi announced that her department's Civil Rights Division dismissed the lawsuit in a statement Monday that said the Justice Department "does not believe challenging Tennessee's law serves the public interest." Gender-affirming care includes a range of therapies, including psychological, behavioral and medical interventions, with surgeries for minors being exceedingly rare. According to a recent Harvard study, cisgender minors and adults were far more likely to undergo analogous gender-affirming surgeries than their transgender counterparts. Every major American medical association supports gender-affirming care for both adults and minors, including the American Academy of Pediatrics and the American Medical Association, the largest national medical association. Despite the support of the medical community and evidence of its efficacy, gender-affirming care and this marginalized community continue to be targeted by conservatives and Republicans with legislation. Tennessee enacted Senate Bill 1 in March 2023 to prohibit healthcare professionals from prescribing puberty blockers or hormones to minors to treat gender dysphoria, which attracted a lawsuit from the Justice Department under President Joe Biden, arguing the law violated the 14th Amendment's Equal Protection Clause, as all other minors continued to have access to the same procedures and treatments. The conservative movement targeting the healthcare of transgender minors has since gained a supporter in the White House with the re-election of President Donald Trump. Since returning to power, Trump has implemented an agenda targeting transgender Americans, including directing the federal government to recognize only two sexes determined at "conception," restricting gender-affirming care for youth and banning transgender Americans from the military. Last month, the conservative-leaning Supreme Court ruled 6-3 against the Biden administration's complaint to overturn the Tennessee law. The ruling fell along ideological lines, with the conservative justices voting for the law to stand. The liberal justices dissented. "By retreating from meaningful review exactly where it matters most, the Court abandons transgender children and their families to political whims," Justice Sonia Sotomayor said in her dissent. "Tennessee's ban applies no matter what a minor's parents and doctors think, with no regard for the severity of the minor's mental health conditions or the extent to which treatment is medically necessary for an individual child." Bondi on Monday said the Supreme Court made "the right decision." Assistant Attorney General Harmeet Dhillon of the Justice Department's Civil Rights Division said that by dismissing the lawsuit, they "undid one of the injustices the Biden administration inflicted upon the country."
Refinery29
2 hours ago
- Refinery29
Why People Are Swapping Vapes For Cigarettes Despite The Risks
'Cigarettes for me were a form of nicotine that I was able to have more 'control' over than vaping,' says Ellie*, 29, from New York. It isn't just Ellie who thinks this. When vapes spiked in popularity, the marketing of them as a way to cut back on cigarettes pervaded. This messaging is even backed by the NHS, where the advice on nicotine vapes is that they are 'one of the most effective stop smoking aids'. The FDA however, hasn't approved of vapes for this use in the U.S. The science repeatedly says they're less damaging than cigarettes. And yet, people are now switching back to smoking in an attempt to cut out vaping for good. What's more, they're convinced it's better for them. There's a disconnect between what the experts say and what smokers think about the health risks. Ellie is a prime example of this. 'While cigarettes are indisputably dangerous and cancer-causing, I actually know what's in them, and the long-term effects are documented,' she says. 'Because vapes are a newer invention, we don't yet know what the full risks are,' Ellie adds. She isn't alone in her perspective. A survey on smoking in England, updated this month, found that current smokers believe vapes are 'equally or more harmful' than cigarettes, despite the NHS again affirming that vaping more frequently than smoking doesn't make them worse. New research from Action on Smoking and Health (ASH) concludes that vapes are being 'underused' to quit smoking and that the public is 'confused' about the health risks posed by vapes. Their data found that 63% of young people think vaping is as harmful or more harmful than smoking. Just last year, their survey showed 50% of people felt this way, so the public health disconnect is growing. Perceptions have shifted back in favour of cigarettes, not because people are misinformed and unaware of the cancer risks. They know them well. Instead, it's the lack of decades long research on vapes that we have on cigarettes that's swinging people away from vaping. Ellie's smoking habit began, like many people, as a result of working around other smokers. 'I realised while working at a restaurant that my coworkers who were smokers (which was most of them) were able to get 'smoke breaks' during their shifts that non-smokers were not given. It was both a way to be social with my coworkers during and after shifts, and gave me a reason to step outside for a moment during the work day.' Then as a sophomore in 2015, she swapped cigarettes for vapes for the next five years. The lure was strong, and strawberry-flavoured. 'The thing about vaping is that unlike cigarettes, I could use them anywhere and everywhere. In bed before I fell asleep and immediately when I woke up, in the bathroom at work or restaurants, and while sitting at my desk when working from home, while sitting on the couch watching a movie with friends,' says Ellie. When she looked into it, she found that one Juul pod has the same amount of nicotine as around 20 cigarettes. At the height of Ellie's addiction, she was 'easily' going through a pod every day and a half or so — whereas during her first time as a cigarette smoker, she was smoking five or six cigarettes a day at the peak. Upon doing the maths, she became deeply concerned about the amount of nicotine she was consuming. 'I had read studies about how long-term vaping can damage your blood vessels and cause ' popcorn lung ' [ editor's note: Diacetyl is the risky ingredient linked to popcorn lung. In the UK it's banned from vapes, but is still allowed in the U.S. Vaping without this ingredient does not cause popcorn lung ]. After a friend posted about how they were hospitalised for possibly permanent damage to their blood vessels as a result of heavy vaping, I decided I wanted to stop, and used cigarettes to help me wean off.' Ellie shared some of her research with me, and it is alarming. There's concern about the toxic metals contained within them, for example, and concerns around their regulation globally. These scares have contributed to the false idea that vaping is worse than smoking. The new generation of nicotine-users are worried about the speed at which they run through a vape. So, after briefly fading from fashion among younger people, cigarettes now had a place in their eyes once more. Hazel Cheeseman, chief executive of Action on Smoking and Health, tells Refinery29 this trend is a serious concern. 'While we may not have decades of data we have on smoking we have more than enough to know that smoking is so much more of a risk to your health,' Cheeseman says. 'People are not 'addicted to smoking' or 'addicted to vaping' — they are addicted to nicotine. When people feel they vape more than they smoke, this is because the vape delivers nicotine in a different way to cigarettes [which is far less rapid], not because they are more addicted.' Cheeseman is clear that much more needs to be done to make sure people understand the risks better. Up to two thirds of long-term smokers die prematurely from smoking related illness. 'If people believe cigarettes are a healthier choice they are completely misguided,' says Cheeseman. It's a damning reality, but one that isn't seeming to impress itself on people, who truly believe cigarettes have helped them. Jenny*, 27, who lives in London, thinks vapes made her 'way more addicted to nicotine' compared with when she socially smoked cigarettes, having been an on and off smoker since her teenage years. Like Ellie, she would vape at any given opportunity at home or out of the house. Jenny began to notice she was becoming short of breath at the gym. Though aware of the risks attached to cigarettes, she's found it easier to have periods where she completely stops smoking compared with when she vaped. At the start of this year, Jenny decided to quit for two and a half months. Now that it's festival season, she wants to socially smoke again. But the kicker for her though, is cigarettes haven't become a daily habit like vaping grew to be. 'I see it now as a treat,' says Jenny. 'Switching back to cigarettes has given me a better relationship with my smoking. I've seen friends who never touched cigs now be in a complete state of panic and distress when they lose their Lost Marys. It's insane. The fact we can do it anywhere, just makes it far too accessible.' And while it's less of a concern than the health side of things, Jenny adds: 'You look impossibly unchic having a vape'. Mistrust of vapes, in the UK at least, seemed to gain momentum in some circles when the disposable vape ban came into effect in June this year. Lewis*, 31, from London, previously smoked, quit, started to vape, then decided to switch back in line with the ban. 'It seemed like a good moment to finally kick the habit,' he says. 'Plus a lot of my friends used this arbitrary date too, so there was strength in numbers.' When socialising, Lewis says he needs something to 'break up' the night. 'The pub setting is the most challenging, with the combination of beer, friends, and outdoor space. It's just too tempting, and I saw the occasional fag as a much less unhealthy and expensive than chugging three to four vapes a week.' Although he too knows the risks of cigarettes, he found quitting in the past easy so isn't worried about that side of things. 'I much prefer vaping. It's tastier, doesn't make your clothes smell, and for me it's much more addictive, so I'm not concerned I'll become a full-time smoker as I genuinely don't like it as much,' says Lewis. Since smoking cigarettes, Lewis says his 'vape cravings' have lessened and that he's barely thought about them. 'I know the science says vaping is less harmful, however there are still a lot of unknowns, especially related to heavy metals, microplastics, and the long term effects. Most people aren't chain-smoking one after another. So for me, it's definitely a 'healthier' choice considering that I smoke much less than I vaped.' Currently, he smokes five to 10 cigarettes a week and plans to keep an eye on it so the habit doesn't grow. He's also considered snus (a smokeless tobacco people place under their lip), but that doesn't always react well with him. The people I've interviewed aren't stupid: they know the risks, they never were chain-smokers, they think there's nuance missing from the advice for people like themselves with more socially-led habits. Dr Deborah Lee, of Dr Fox Online Pharmacy, says that yes, it's true that cigarettes contain less nicotine than many vapes. 'Some vapes contain 40 mg of nicotine — 400-600 puffs. This is equivalent to smoking one to two packs of cigarettes. Illegally sold vapes may contain even higher amounts of nicotine. So, converting from vapes to cigarettes would result in less nicotine exposure, depending on how many cigarettes are smoked.' But, Lee makes it clear this isn't where the health piece ends. 'When you light a cigarette, tobacco is burning, and you inhale cigarette smoke into your lungs which contains over 5000 noxious substances including over 50 known carcinogens. E-cigarettes and vapes deliver nicotine without exposure to the harms of cigarette smoke.' Nicotine is the lesser evil, and yet it's what many smokers tend to focus on. Vaping isn't perfect, though, and it doesn't come without its own risks to a person's health. Lee shares that a 2020 review concluded that vaping has a similar effect on respiratory and cardiac function as smoking. 'Over time, vaping causes constriction of the smaller airways and damage to the lung epithelium like smoking. Vaping also increases blood pressure and causes arterial stiffness.' Essentially, more research is needed. For a generation of people used to getting answers at the tap of a search bar, the lack of data isn't helping faith in vaping over smoking. 'While research shows the most successful ways to stop smoking involve behavioural treatment programs with nicotine replacement products (which can include vapes), varenicline and bupropion, a 2017 meta-analysis of 38 studies found that smokers were 28% less likely to quit if they used e-cigarettes. Other studies have had similar results,' Lee adds. This is where people are turning to what feels best for them personally. Ellie says going back to cigarettes helped her quit vapes in just a few days. 'If it was freezing cold or rainy outside, I'd find myself not willing to go out for a cigarette. Cigarettes helped me lessen the oral fixation as I can't smoke them at my desk, and I feel satisfied with smaller hits of nicotine spaced throughout the day. I can't imagine ever going back to vaping. The convenience of it made my addiction feel stronger and more constant than anything I'd experienced before. While I could easily finish a Juul pod in a day or so, I couldn't possibly smoke 20 American Spirits in 24 hours without feeling seriously ill.' There's no data on how effective smoking can be to quit vapes, but Ellie is giving it a try nonetheless. She wants to quit everything before turning 30. *Names have been changed to protect identities.
